

Please Fax Completed Form To: 800-783-9146

PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION	
Name: DOB:			
Address:		State License:	
City, State, Zip:		DEA: Address:	
Phone: Alt. Phone:			
Email:SS#:			Fax:
Gender: 🗆 M 🗆 F Weight:(lbs) Ht:		-	Phone:
INSURANCE INFORMATION – OR – Send a copy of the patient's prescription/insurance cards (front & back)			
Primary Insurance:			
City, State, Zip:			
Plan #:			
Group #:			
Phone:		Phone:	
CLINICAL INFORMATION			
Primary ICD-10 code:		NKDA     Known drug allergies:	
Pregnant:  Yes  No		Concurrent Meds:	
Expected date of first/next injection:		Date of last injection (if relevant):	
Agency nurse to visit home for injection: 2 Yes 2 No		Agency name & telephone:	
(DRUG NAME) ORDERS – this section may not be needed)			
Prescription type:  New start  Restart	□ Continued therapy Tota	I Doses Received:	Date of Last Infusion/Injection:
Medication		Directions	Quantity/Refills
□ Copaxone® 20mg PFS □ Copaxone® 40 mg PFS	<ul> <li>Inject 20mg subcutaneously daily.</li> <li>Inject 40mg subcutaneously three times a week.</li> <li>Other:</li> </ul>		<ul> <li>30-day supply (1 kit/30 syr)</li> <li>90-day supply (3 kits/90 syr)</li> <li>Refills:</li> <li>28-day supply (1 kit/12 syr)</li> <li>84-day supply (3 kits/36 syr)</li> <li>Refills:</li> </ul>
Glatiramer acetate or Glatopa	<ul> <li>Inject 20mg subcutaneously daily.</li> <li>Inject 40mg subcutaneously three times a week.</li> <li>Other:</li> </ul>		□ 30-day supply (1 kit/30 syr) □ 90-day supply (3 kits/90 syr) Refills: □ 28-day supply (1 kit/12 syr) □ 84-day supply (3 kits/36 syr) Refills:
Pre-medication:			
SIGNATURE			
X			Date:
Prescriber Signature			

BioTek

**%reMEDys** 

**CONFIDENTIALITY STATEMENT:** This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.